Market: NASD |
Currency: USD
Address: 2701 Eastlake Avenue East
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
📈 Nautilus Biotechnology, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$2.50
-
Upside/Downside from Analyst Target:
177.10%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-10-28
-
EPS Estimate:
-0.15
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Nautilus Biotechnology, Inc.
Date | Reported EPS |
---|
2025-10-28 (estimated upcoming) | - |
2025-07-31 | -0.12 |
2025-04-29 | -0.13 |
2025-02-27 | -0.14 |
2024-10-29 | -0.13 |
2024-07-30 | -0.14 |
2024-04-30 | -0.15 |
2024-02-28 | -0.14 |
2023-10-31 | -0.13 |
2023-08-02 | -0.13 |
2023-05-02 | -0.12 |
2023-02-23 | -0.11 |
2022-11-01 | -0.11 |
2022-08-02 | -0.12 |
2022-05-03 | -0.13 |
2022-02-24 | -0.13 |
2021-11-02 | -0.12 |
2021-08-10 | -0.19 |
📰 Related News & Research
No related articles found for "nautilus biotechnology".